Physician profile
Richard E Cain
NPI 1003811472
$4,410.36
in general payments reported to CMS, 2019-2025
29 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $358 · 2021: $626 · 2022: $1,024 · 2023: $811 · 2024: $1,142 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $822.21 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $746.04 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $441.51 | 2021-2025 | Vraylar, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.60 | 2020-2024 | Jardiance, Spiriva Respimat |
| Amarin Pharma, INC. | $252.42 | 2019-2021 | |
| Lilly USA, LLC | $249.86 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $218.94 | 2020-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $200.47 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $150.00 | 2023 | Comprehensive Shoulder System |
| Pfizer INC. | $122.26 | 2022-2024 | |
| Astellas Pharma US INC | $116.68 | 2022-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $79.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $74.53 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.48 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.93 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $61.24 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $42.28 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $38.60 | 2022-2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $35.88 | 2025 | Watchman Access System |
| Phathom Pharmaceuticals, INC. | $34.63 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $29.80 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $27.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.04 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.71 | 2025 | Fanapt |
| Aimmune Therapeutics, INC. | $18.75 | 2024 | |
| Ironshore Pharmaceuticals INC. | $14.69 | 2023 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $14.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.95 | 2021 | |
| Ortho-Clinical Diagnostics, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.